SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is currently trending due to unconfirmed but persistent market speculation regarding a potential multibillion-dollar acquisition by a larger biopharmaceutical player. Investors are actively debating the company's valuation, comparing recent pipeline advancements and commercial performance to previous sector buyouts while awaiting further news to validate the significant uptick in trading volume and price action.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as a highly speculative meme coin, triggering intense debate between traders hoping for rapid gains and community members warning of a potential rug pull due to extreme holder concentration. While some enthusiasts highlight its volatile price movements and aggressive social media promotion, many skeptics view the asset as a classic pump-and-dump scheme with no inherent utility.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund, trading as VCX, has experienced significant volatility and massive price premiums over its net asset value since its recent IPO, with investors heavily focused on its portfolio of private AI giants like Anthropic and SpaceX. Much of the community conversation is centered on the six-month lockup period affecting early shareholders, fueling heated debates between those holding for long-term growth and others bracing for a potential price correction.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is generating significant buzz as investors weigh upcoming earnings reports against expectations for a major NASA Lunar Terrain Vehicle (LTV) contract award. The community remains deeply divided, with bulls pointing to strong forward revenue guidance and long-term space infrastructure growth, while bears emphasize execution risks and the volatility associated with contract timing.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is currently generating intense debate among retail traders, with bulls pointing to edge computing and AI exposure as catalysts for a massive run, while bears warn of extreme overvaluation and heavy insider selling. The community is sharply divided between those who believe the stock is undergoing a legitimate short squeeze and those convinced it is a manipulated pump-and-dump scheme.

CBIZ, Inc. is a professional services advisor to middle market businesses and organizations nationwide. It offers its services in accounting, tax, advisory, benefits, insurance, and technology. The firm delivers forward-thinking insights and actionable solutions to help clients anticipate what's next and discover new ways to accelerate growth. It operates through the following segments: Financial Services, Benefits and Insurance Services and National Practices. The Financial Services segment offers accounting, tax, government health care consulting, financial advisory, valuation, and risk advisory services. The Benefits and Insurance Services segment includes group health benefits consulting, property and casualty brokerage, retirement plan services, and payroll. The National Practices segment deals with managed networking and hardware, and healthcare consulting. The company was founded by Michael G. DeGroote Sr. in 1987 and is headquartered in Independence, OH.

Cbiz Inc

Investors are actively debating the long-term outlook for CBIZ as the firm navigates integration challenges following major mergers. Discussions highlight concerns over recent financial performance and debt levels, while the community remains divided between those viewing the current valuation as an oversold opportunity and others wary of ongoing corporate headwinds.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis is trending as investor interest surges following the company's recent Medicare coverage approval for its NeXT Personal MRD test in breast cancer, a major milestone that removes a key barrier to commercial scaling. Community sentiment is overwhelmingly bullish, with active discussions focusing on the companys potential as a takeover target, its deep integration with Tempus AI, and the expected rapid revenue expansion as additional oncology indications secure regulatory reimbursement.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

Investors are actively discussing 4CHAN as a "cultural index" or "source code" for the broader meme coin market, citing its status as the original birthplace of internet memes as a key value proposition. The community is focused on the token's high liquidity and scarcity model, often comparing its potential to Bitcoin or major memecoins while viewing current market volatility as a prime accumulation window for long-term holders.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is experiencing heightened volatility and intense social media chatter as investors brace for a critical upcoming earnings report and potential acquisition developments. Community sentiment remains deeply polarized between long-term holders anticipating a business transformation and skeptical traders concerned about recent price stagnation and transparency.

Apollo Global Management, Inc. provides asset management services. It offers its clients excess return at every point along the risk-reward spectrum from investment grade to private equity with a focus on three business strategies: yield, hybrid, and equity. It operates through following segments: Asset Management, Retirement Services and Principal Investing. The Asset Management segment focuses on credit and equity investing strategies. The Retirement Services and Principal Investing segment consists of realized performance fee income, realized investment income from balance sheet investments, and certain allocable expenses related to corporate functions supporting the entire company. The company was founded by Marc Rowan in 1990 and is headquartered in New York, NY.

Apollo Global Management Inc

Apollo Global Management is currently in focus as investors analyze the firm's strategic positioning within the private credit sector and its potential for long-term growth driven by robust asset management inflows. The community is actively discussing the firm's ability to maintain performance amidst evolving macro conditions, while keeping a close watch on leadership insights regarding market stability and capital deployment strategies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The acquisition is expected to boost Servier’s position in pediatric low-grade glioma treatments.</li><li>This acquisition aligns with Servier’s long-term strategy to develop innovative oncology treatments by 2030.</li><li>In February, Day One reported strong momentum for its lead therapy, OJEMDA.</li></ul>Day One Biopharmaceuticals, Inc. (DAWN) announced on Friday that it has entered into an acquisition agreement with Servier, an independent pharmaceutical company managed by a foundation.The deal, valued at roughly $2.5 billion, will see Servier purchase Day One shares for $21.50 each in cash, marking a 64% premium over DAWN’s closing price on Thursday.<h2 class="st-heading-2">Expansion In Oncology</h2>The acquisition is expected to boost Servier’s position in pediatric low-grade glioma treatments and broaden its cancer pipeline for both adults and children facing high unmet medical needs.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/DAWN">Day One Biopharmaceuticals stock</a> surged over 65% on Friday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.<h2 class="st-heading-2">Pipeline Growth And 2030 Ambition</h2>This acquisition aligns with Servier’s long-term strategy to develop innovative oncology treatments by 2030. The addition of Day One’s programs, ranging from early-stage research to phase 3 trials, enhances Servier’s capacity to deliver solutions for cancers with critical unmet needs.<blockquote>“Joining Servier represents a unique opportunity to extend the reach of our science and our lead program in pediatric low‑grade glioma.”-Jeremy Bender, CEO, Day One</blockquote>In February, Day One&nbsp;reported strong momentum for its lead therapy, OJEMDA, highlighting prescription volumes for OJEMDA reached 1,394 in the fourth quarter of 2025, with total prescriptions for the year at 4,635, marking a 181% year-on-year (YOY) growth.&nbsp;The company said updated three-year results from the Phase 2 FIREFLY-1 trial demonstrated durable responses and long-term safety of OJEMDA in relapsed or refractory pediatric low-grade glioma (pLGG). Enrollment for the pivotal Phase 3 FIREFLY-2 trial evaluating OJEMDA in frontline pLGG remains on schedule, with full enrollment expected in the first half of 2026.DAWN stock traded over 132% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/aspi-stock-in-spotlight-as-company-strengthens-us-nuclear-fuel-supply-chain-with-new-deal/cZdLbbRRIEr">ASPI Stock In Spotlight As Company Strengthens US Nuclear Fuel Supply Chain With New Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Day One Biopharmaceuticals logo is displayed on the screen of a tablet.

Why Did DAWN Skyrocket Over 65% Pre-Market Today? 

Pharma firm Servier is set to acquire Day One Biopharmaceuticals’ shares for $21.50 each in cash, valuing the deal at $2.5 billion.

Equity

Pharma firm Servier is set to acquire Day One Biopharmaceuticals’ shares for $21.50 each in cash, valuing the deal at $2.5 billion.


<ul class="summary-bullets"><li>The company reported Q4 revenue of $92.02 million with an earnings per share (EPS) of $0.15.</li><li>Since the&nbsp;YUTREPIA launch, the company has received more than 3,600 unique prescriptions.</li><li>The therapy’s adoption rate has remained strong, with the conversion from prescription to patient treatment staying at or above 85%.</li></ul>Liquidia Corp. (LQDA) on Thursday released its financial results for the fourth quarter (Q4), highlighting strong early traction in the commercial rollout of its respiratory drug, YUTREPIA.&nbsp;The company reported Q4 revenue of $92.02 million&nbsp;with an earnings per share (EPS) of $0.15. While revenue surpassed the analysts’ consensus estimate of $83.70 million, EPS came in below the $0.19 estimate, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">YUTREPIA Launch Drives Commercial Momentum</h2>The North Carolina-based company reported significant prescription growth for YUTREPIA since its U.S. launch in June 2025, with thousands of patients now receiving therapy. The drug’s early performance has become a key contributor to Liquidia’s improving financial outlook and operational momentum.Product revenue from YUTREPIA reached approximately $148.3 million in 2025,&nbsp;including about $90.1 million generated during the fourth quarter alone.<blockquote>“We believe YUTREPIA and L606 have the potential to establish a new standard for the use of inhaled prostacyclin as a critical therapeutic modality across serious and progressive cardiopulmonary diseases.”-Roger Jeffs, CEO, Liquidia&nbsp;</blockquote>Following the update,&nbsp;<a href="https://stocktwits.com/symbol/LQDA">Liquidia’s stock</a> traded over 6% higher in Thursday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume flipped to ‘high’ from ‘normal’ in 24 hours.&nbsp;<h2 class="st-heading-2">What’s Next?&nbsp;</h2>Since the&nbsp;YUTREPIA launch, the company has received more than 3,600 unique prescriptions, with over 2,900 patients already starting treatment. The therapy’s adoption rate has remained strong, with the conversion from prescription to patient treatment staying at or above 85%.Jeffs said the company plans to increase the number of doctors prescribing the treatment, expand the sales team, add more clinical data for YUTREPIA through several new studies, and move L606 into key late-stage trials, all using funds generated from business operations.LQDA stock has gained over 121% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/meta-lacks-deep-pool-of-cloud-demand-unlike-google-and-amazon-says-arete/cZdQYbhRI3T">Meta Lacks The 'Deep Pool' Of Cloud Demand, Unlike Google And Amazon, Says Arete</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Liquidia Corporation logo is seen displayed on a smartphone screen.

Liquidia Stock Gains Premarket On Q4 Revenue Beat – Investors Are Betting On YUTREPIA Growth 

Product revenue from YUTREPIA reached approximately $148.3 million in 2025, including about $90.1 million generated during the fourth quarter alone.

<ul class="summary-bullets"><li>The study enrolled 366 patients, who were randomized to receive either BCG alone or ANKTIVA in combination with BCG.</li><li>Interim analysis of the Phase 2 trial showed 84% of patients on the combo maintained a complete response, compared to 52% on BCG alone at nine months.</li><li>ImmunityBio’s 431% revenue growth in Q4 was largely driven by ANKTIVA sales, the company said.</li></ul>Shares of ImmunityBio (IBRX) reversed pre-market gains to trade 3% lower on Thursday&nbsp;after the company completed enrollment ahead of schedule in its Phase 2 ANKTIVA trial and reported that an FDA-requested interim analysis showed significantly longer complete responses with no major safety concerns.The Phase 2 trial studied ANKTIVA plus Bacillus Calmette-Guérin (BCG) in patients with BCG-naïve non-muscle invasive bladder cancer. The study enrolled 366 patients, who were randomized to receive either BCG alone or ANKTIVA in combination with BCG.The company plans to submit a biologics license application by the fourth quarter of 2026.&nbsp;Last week, the European Commission <a href="https://stocktwits.com/news-articles/markets/equity/immunitybio-inks-partnerships-to-launch-cancer-drug-in-saudi-arabia/cZRNf8cR4xF">granted</a> conditional marketing approval for Anktiva to treat BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.<h2 class="st-heading-2">ANKTIVA-BCG Combo Significantly Improves Complete Response Duration</h2>An interim analysis requested by the U.S. Food and Drug Administration (FDA) showed that the combination significantly improved the duration of complete response, with no major safety concerns. At nine months, 84% of patients on the combo maintained a complete response, compared with 52% on BCG alone.“We are encouraged by these interim results and await the final unblinding of the completed trial. If approved, ANKTIVA plus BCG could offer a new treatment option earlier in the disease course for patients with NMIBC CIS, building on the therapy’s existing approval in the BCG-unresponsive setting,” said Patrick Soon-Shiong, Chairman and Global Chief Scientific and Medical Officer of ImmunityBio.ANKTIVA continues to power ImmunityBio’s growth, with fourth-quarter net product revenue soaring 431% to $38.3 million, beating Wall Street expectations on strong sales of the drug.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on for <a href="https://stocktwits.com/symbol/IBRX/sentiment">IBRX</a> Stocktwits has remained ‘extremely bullish’ zone for the past six months, while message volumes have been ‘extremely high’.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_b893b9958b.webp" alt="IBRX.jpg">One user said the trial’s outcome is strong enough to justify considering Anktiva + BCG as the “standard of care in BCG-naive NMIBC.”<stembedurl>https://stocktwits.com/Adi121/message/645956934</stembedurl>Another user expects consolidation before the next leg of the rally.<stembedurl>https://stocktwits.com/Texas12/message/645972831</stembedurl>Year-to-date, the stock has shot up 350%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

IBRX Stock Reverses Pre-Market Gains After ANKTIVA Combo Shows Stronger Bladder Cancer Responses – Retail Sees Consolidation Before Next Leg Up

The company said it plans to submit a biologics license application by the fourth quarter of 2026.

Biotech ETFs Hovering Around a 52-Week: Here's Why 

Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the rebound just starting?

Biotech ETFs Bounce Back in 2025: Here's Why  

Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.

BBP
ETFis Series Trust I - Virtus LifeSci Biotech Products ETF

Feed

News

Sentiment

Fundamentals

Info

Latest BBP News

BBPETFis Series Trust I - Virtus LifeSci Biotech Products ETF